BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech ...

We will also explore the utility of mouse bispecific antibodies in basic research and drug discovery, featuring specific examples of their application. Attendees will learn how the high-throughput ...

Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

The acquisition boosts BioNTech’s mRNA design and manufacturing capabilities, accelerating development of next-gen cancer ...

A new kind of cancer treatment is emerging—one that turns the patient’s own body into a drug factory. Here's what you need to ...

It is currently being tested in a Phase I clinical study (BBT001-001; NCT06808477) BBT002 is a novel half-life extended bispecific antibody designed as a "platform in a molecule" with broad ...

Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of ...

AbTherx's highly efficient research planning and partnering process enabled Wield, an early-stage startup, to achieve concept-to-collaboration within weeks MOUNTAIN VIEW, CA / ACCESS Newswire / June 1 ...